Avoid common mistakes on your manuscript.
Fluorine-18 fluoroacetate [1] appears to be an interesting alternative to 11C-acetate [2, 3] for imaging prostate cancer with PET. We acquired the first 18F-fluoroacetate PET images in a patient with prostate cancer, rising PSA (101 ng/ml) and progressive bone metastases. Scanning started 70 min after i.v. injection of 280 MBq 18F-fluoroacetate using a combined PET/CT system (Siemens Biograph).
The images demonstrate moderate to intense uptake in several (thick arrows) but not all (thin arrows) metastatic bone lesions, with SUVmean of 2.82–4.10 and SUVmax of 3.36–5.11. This compared favourably to accumulation in the liver, with SUVmean of 2.35–2.71 and SUVmax of 3.0–3.58. The mode of excretion was predominantly via the bowel (arrowheads), with low activity in the urine.
Compared with 11C-acetate PET, 18F-fluoroacetate offers the possibility of delayed imaging with the potential to further increase the tumour-to-background ratios.
Upper row: CT image slices; middle row: combined 18F-fluoroacetate PET/CT; lower row : 18F-fluoroacetate PET
References
Ponde DE, Oyama N, Dence CS, Welch MJ.18F-fluoroacetate, an analogue of C-11 acetate for tumour imaging [abstract]. J Nucl Med 2003; 44:1062.
Oyama N, Miller TR, Dehdashti F, et al.11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44:549–555.
Fricke E, Machtens S, Hofmann M, et al. Positron emission tomography with11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003; 30:607–611.
Author information
Authors and Affiliations
Corresponding author
Additional information
Rights and permissions
About this article
Cite this article
Matthies, A., Ezziddin, S., Ulrich, EM. et al. Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT. Eur J Nucl Med Mol Imaging 31, 797 (2004). https://doi.org/10.1007/s00259-003-1437-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-003-1437-1